China Virtual Clinical Trials Market Size & Outlook
Related Markets
China virtual clinical trials market highlights
- The China virtual clinical trials market generated a revenue of USD 450.9 million in 2023 and is expected to reach USD 717.4 million by 2030.
- The China market is expected to grow at a CAGR of 6.8% from 2024 to 2030.
- In terms of segment, interventional was the largest revenue generating study design in 2023.
- Expanded Access is the most lucrative study design segment registering the fastest growth during the forecast period.
Virtual clinical trials market data book summary
| Market revenue in 2023 | USD 450.9 million |
| Market revenue in 2030 | USD 717.4 million |
| Growth rate | 6.8% (CAGR from 2024 to 2030) |
| Largest segment | Interventional |
| Fastest growing segment | Expanded Access |
| Historical data | 2017 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Interventional, Observational, Expanded Access |
| Key market players worldwide | Icon PLC, PAREXEL, IQVIA Holdings Inc, Labcorp Holdings Inc, LEO Pharma, Medidata, Oracle Corp, Signant Health |
Other key industry trends
- In terms of revenue, China accounted for 5.2% of the global virtual clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China virtual clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 377.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Virtual Clinical Trials Market Scope
Virtual Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Signant Health | View profile | 1001-5000 | Blue Bell, Pennsylvania, United States, North America | https://www.signanthealth.com/ |
| Medidata | View profile | 1001-5000 | New York, New York, United States, North America | https://www.medidata.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.parexel.com |
| IQVIA Holdings Inc | View profile | 87000 | 2400 Ellis Road, Durham, NC, United States, 27703 | https://www.iqvia.com |
| LEO Pharma | View profile | 1001-5000 | Parsippany, New Jersey, United States, North America | http://www.leo-pharma.us/ |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Oracle Corp | View profile | 164000 | 2300 Oracle Way, Austin, TX, United States, 78741 | https://www.oracle.com |
China virtual clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to virtual clinical trials market will help companies and investors design strategic landscapes.
Interventional was the largest segment with a revenue share of 50.14% in 2023. Horizon Databook has segmented the China virtual clinical trials market based on interventional, observational, expanded access covering the revenue growth of each sub-segment from 2018 to 2030.
China accounted for the largest market share of 27.7% in 2020. Rising investments in R&D are among the major factors responsible for market growth. As per a research article published by Dennis Normile in 2020, the R&D spending accounted for 2.23% of GDP, which led to an increase of 0.09% from the previous year.
Increasing healthcare digitalization is also responsible for market growth of virtual clinical trials in China. China has the second largest healthcare industry after the U.S. Moreover, China’s digital healthcare market was already positioned to reach USD 3.29 billion by 2020.
However, COVID 19 outbreak has initiated a massive hastening in the use of telehealth services. Moreover, there is increasing interest in decentralized clinical trials in China. The Chinese government recently issued a plan of action to encourage virtual clinical trials to accelerate development & reduce face-to-face interactions required in traditional trials as a response to COVID-19.
Reasons to subscribe to China virtual clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China virtual clinical trials market databook
-
Our clientele includes a mix of virtual clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China virtual clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into China virtual clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China virtual clinical trials market size, by study design, 2017-2030 (US$M)
China Virtual Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
